Slingshot Insights | Rhhby Overview

RHHBY Overview

Upcoming Projects (RHHBY)

Angelman Syndrome Pipeline: Recent Updates on GTX-102 (Ultragenyx & GeneTx), ION582 (Ionis Pharmaceuticals), and rugonersen (Roche).
Tickers: RARE, IONS, RHHBY
Scheduled For: May 12, 2025 at 04:00 PM EDT
Reviewing Phase III MUSETTE Trial Results for High-Dose OCREVUS in Relapsing Multiple Sclerosis from Roche
Ticker: RHHBY
Execute By: Aug 31, 2025

Executed Projects (RHHBY)

Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Polivy April 2025
Ticker: RHHBY
Executed On: Apr 25, 2025 at 03:36 PM EDT
Looking at Roche's cobas® liat molecular test for point-of-care screening of sexually transmitted infections
Ticker: RHHBY
Executed On: Mar 27, 2025 at 08:30 AM EDT
Two Week Delay: Survey on Market Share Outlook covering Tyenne (tocilizumab-aazg) and Actemra (tocilizumab) in EU/US February 2025
Tickers: FSNUF, BIIB, Celltrion, RHHBY, FMEA.XFRA
Executed On: Mar 14, 2025 at 09:41 AM EDT
Looking at Roche's SBX Technology and how it is differentiated in the Next-Generation-Sequencing (NGS) space
Tickers: RHHBY, ILMN, PACB, TXG, BRKR, Ultima Genomics, element biosciences
Executed On: Mar 04, 2025 at 11:00 AM EST
A Third Opinion: Looking at Regenxbio's Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD
Tickers: RGNX, FDMT, ABBV, RHHBY, REGN
Executed On: Feb 28, 2025 at 02:00 PM EST
A Second Opinion: Looking at Regenxbio's Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD
Tickers: RGNX, FDMT, ABBV, RHHBY, REGN
Executed On: Feb 27, 2025 at 02:00 PM EST
Looking at Regenxbio's Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD
Tickers: RGNX, FDMT, ABBV, RHHBY, REGN
Executed On: Feb 24, 2025 at 02:00 PM EST
A Second Discussion: Understanding the impact of Eylea biosimilars on the wet-AMD market
Tickers: REGN, RHHBY, AMGN
Executed On: Feb 14, 2025 at 03:30 PM EST
Assessing the RESILIENT SMA Trial Results for Taldefgrobep Alfa in Spinal Muscular Atrophy from Biohaven Pharmaceuticals
Tickers: BHVN, RHHBY, BIIB, NVS
Executed On: Feb 07, 2025 at 09:00 AM EST
Understanding the impact of Eylea biosimilars on the wet-AMD market
Tickers: REGN, RHHBY, AMGN
Executed On: Feb 06, 2025 at 07:30 AM EST
Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Polivy January 2025
Ticker: RHHBY
Executed On: Jan 28, 2025 at 11:13 AM EST
Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Polivy October 2024
Ticker: RHHBY
Executed On: Nov 01, 2024 at 01:59 PM EDT
Discussing the recent FDA approval of Ocrevus Zunovo for the treatment of multiple sclerosis.
Ticker: RHHBY
Executed On: Oct 24, 2024 at 12:00 PM EDT
A Second Look: Discussing current uptake for Regeneron's Eylea (aflibercept) HD uptake and Roche Vabysmo
Tickers: REGN, RHHBY
Executed On: Sep 09, 2024 at 02:30 PM EDT
Discussing current uptake for Regeneron's Eylea (aflibercept) HD uptake and Roche Vabysmo
Tickers: REGN, RHHBY
Executed On: Aug 29, 2024 at 04:30 PM EDT
Discussing the AMPLIFY Phase III trial of Calquence plus venetoclax as a first line treatment for chronic lymphocytic leukemia
Tickers: AZN, ABBV, RHHBY
Executed On: Aug 29, 2024 at 12:00 PM EDT
Discussing the recent label expansion for Genentech's Alecensa (alectinib) as first adjuvant treatment for people With ALK-Positive Early-Stage Lung Cancer.
Ticker: RHHBY
Executed On: Aug 27, 2024 at 02:00 PM EDT
Discussing the use of myostatin inhibitors in SMA
Tickers: BHVN, SRRK, RHHBY
Executed On: Aug 20, 2024 at 11:00 AM EDT
Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Polivy July 2024
Ticker: RHHBY
Executed On: Jul 26, 2024 at 12:51 PM EDT
Discussing the potential of Roche's Susvimo, a surgical ocular implant designed to slowly release ranibizumab for the treatment of Wet-AMD.
Tickers: RHHBY, REGN, OCUL, EYPT
Executed On: Jul 18, 2024 at 03:00 PM EDT
A second look: Discussing Regeneron's Eylea (aflibercept) HD uptake and trends following the April 1 J-Code
Tickers: REGN, RHHBY
Executed On: Jul 12, 2024 at 02:00 PM EDT
Discussing Regeneron's Eylea (aflibercept) HD uptake and trends following the April 1 J-Code
Tickers: REGN, RHHBY
Executed On: Jul 11, 2024 at 04:30 PM EDT
Discussing the current treatment landscape for retinal diseases with a prescriber of Eylea and Vabysmo.
Tickers: REGN, RHHBY
Executed On: May 16, 2024 at 10:15 AM EDT
Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Polivy April 2024
Ticker: RHHBY
Executed On: Apr 24, 2024 at 04:53 PM EDT
Understanding the latest R&D advances and clinical development trends in obesity management
Tickers: RHHBY, AMGN, AZN
Executed On: Feb 12, 2024 at 03:00 PM EST
Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Polivy January 2024
Ticker: RHHBY
Executed On: Jan 23, 2024 at 05:03 PM EST
Getting a prescriber's take on Coherus' Cimerli and where biosimilars fit into the wet-AMD treatment landscape
Tickers: CHRS, RHHBY
Executed On: Dec 01, 2023 at 11:30 AM EST
Examining the ESMO data on Nuvalent's NVL-655 (ALKove-1 study) and Roche's alectinib (P3 ALINA trial) for ALK+ NSCLC
Tickers: NUVL, RHHBY
Executed On: Nov 20, 2023 at 08:00 AM EST
Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Roche's Polivy October 2023
Ticker: RHHBY
Executed On: Oct 26, 2023 at 04:38 PM EDT
Examining the current treatment landscape and anti myostatin inhibition approaches for Spinal Muscular Atrophy (SMA) including Scholar Rock's apitegromab, Biohaven's taldefgrobep Alfa and Roche's GYM329
Tickers: SRRK, RHHBY
Executed On: Oct 25, 2023 at 08:00 AM EDT
Getting a prescriber's perspective comparing Briumvi, Ocrevus and Kesimpta in treating multiple sclerosis
Tickers: TGTX, RHHBY, NVS
Executed On: Oct 03, 2023 at 06:00 PM EDT
Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Roche's Polivy July 2023
Ticker: RHHBY
Executed On: Aug 02, 2023 at 11:15 AM EDT
Discussing the SKYSCRAPER-01 trial of tiragolumab in Non Small Cell Lung Cancer (NSCLC) and readthrough to iTeos/GSK's belrestotug
Tickers: ITOS, GSK, RHHBY
Executed On: Jul 14, 2023 at 01:30 PM EDT
A Second Look: Discussing CD20xCD3 Bispecifics in DLBCL, with a focus on glofitamab & Epcoritamab
Tickers: ABBV, RHHBY
Executed On: Jul 12, 2023 at 11:00 AM EDT
Discussing what's next for Regeneron's high dose Eylea post CRL, current trend of Vabysmo, biosimilars and reimbursement.
Tickers: REGN, RHHBY
Executed On: Jul 10, 2023 at 05:00 PM EDT
Discussing CD20xCD3 Bispecifics in DLBCL, with a focus on glofitamab & Epcoritamab
Tickers: ABBV, RHHBY
Executed On: Jul 06, 2023 at 05:00 PM EDT
A Second Opinion: Reviewing the FDA Breakthrough Device Designation for Roche's Elecsys® Amyloid Plasma Panel for Alzheimer's Disease detection
Tickers: RHHBY, LLY
Executed On: Jun 16, 2023 at 04:00 PM EDT
Reviewing the FDA Breakthrough Device Designation for Roche's Elecsys® Amyloid Plasma Panel for Alzheimer's Disease detection
Tickers: RHHBY, LLY
Executed On: Jun 14, 2023 at 03:00 PM EDT
A Second View: Discussing the potential of CD20 as class in treating Multiple Sclerosis with a focus on BRIUMVI, Kesimpta, and Ocrevus
Tickers: TGTX, NVS, RHHBY
Executed On: May 12, 2023 at 05:00 PM EDT
Discussing the potential of CD20 as class in treating Multiple Sclerosis with a focus on BRIUMVI, Kesimpta, and Ocrevus
Tickers: TGTX, NVS, RHHBY
Executed On: May 11, 2023 at 02:30 PM EDT
Understanding the roles TIGIT targeting drugs play in cancer immunotherapy and efficacy compared to PD-1 inhibitors
Tickers: RHHBY, MRK, GSK, BMS, RCUS
Executed On: May 05, 2023 at 04:30 PM EDT
Reviewing the potential of Algernon Pharmaceutical's experimental lung disease drug, ifenprodil, for patients with IPF
Tickers: AGNPF, RHHBY, Boehringer Ingelheim
Executed On: Feb 22, 2023 at 11:00 AM EST
Discussing the data from the JEWELFISH study on Evrysdi (risdiplam) in treating spinal muscular atrophy (SMA)
Ticker: RHHBY
Executed On: Nov 01, 2022 at 01:00 PM EDT
A review of the current standard of care for Diffuse Large B-Cell Lymphoma and the potential of Roche's Polivy
Ticker: RHHBY
Executed On: Oct 25, 2022 at 02:30 PM EDT

Expired Projects (RHHBY)

Comparing Coherus' Cimerli anti-VEGF with Lucentis in treating Wet AMD
Tickers: CHRS, RHHBY
Execute By: Sep 08, 2022
SURVEY: Understanding the potential impact of Risdiplam on Spinraza in SMA
Tickers: RHHBY, BIIB, NVS
Execute By: Mar 26, 2021
Comparing Roche’s emicizumab (ACE910) recent Phase 3 HAVEN 1 and 2 results to Bioverativ’s FDA approved Eloctate and Alprolix in the treatment of Hemophilia
Tickers: RHHBY, BIVV, SHPG
Execute By: Aug 18, 2017
Evaluating the Chances of Approval and Market Potential of Ariad's Brigatinib in ALK-Positive Non-Small Cell Lung Cancer Before PDUFA of April 29th
Tickers: ARIA, TKPYY, PFE, NVS, RHHBY, Genentech
Execute By: Apr 28, 2017
Discussion of IDO inhibitors from a basic science and research perspective. Specifically discussing potential bioavailability and solubility issues.
Tickers: NLNK, BMY, RHHBY
Execute By: Apr 21, 2017
Expectations for Roche's (RHHBY) Phase 3 Aphinity Data Release Evaluating Perjeta in Adjuvant Treatment of HER2-Positive Breast Cancer. Market Potential and Chances of Approval will be Discussed
Ticker: RHHBY
Execute By: Mar 26, 2017
Electroporation Expert Interview: An Overview and its Pharmaceutical Potential
Tickers: INO, PFE, RHHBY, ROLL
Execute By: Nov 02, 2016
Included with Membership
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016
Assessing the Potential of AstraZeneca's (AZN) Durvalumab + TapImmune's (TPIV) TPIV 200 in Platinum-Resistant Ovarian Cancer Ahead of Phase II Initiation This Quarter
Tickers: AZN, MRK, BMY, TPIV, RHHBY
Execute By: May 17, 2016
Reviewing MedDay Pharmaceuticals's Phase IIb/3 Data For MD1003 in Not-Active Progressive MS, and How it Affects the Market Potential of Roche's (RHHBY) Breakthrough Therapy Ocrelizumab for Primary Progressive Multiple Sclerosis
Tickers: RHHBY, MedDay Pharmaceuticals
Execute By: May 11, 2016
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016

Upcoming & Overdue Catalysts (RHHBY)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (RHHBY)

Roche (RHHBY) announces FDA approval for Venclexta combinations for acute myeloid leukaemia
Ticker: RHHBY
Occurred on: Oct 19, 2020
Phase 3 SUNFISH trial data of PTC Therapeutics'(PTC) Risdiplam in Spinal Muscular Atrophy to be presented at the International Scientific Congress on SMA
Tickers: PTCT, RHHBY
Occurred on: Feb 06, 2020
PDUFA date under priority review for Roche's (RHHBY) Entrectinib in Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC) due August 18, 2019.
Ticker: RHHBY
Occurred on: Aug 16, 2019
Phase 2/3 data of RG7916 in Spinal Muscular Atrophy (SMA) to be presented at AAN May 7, 2019 1pm.
Tickers: PTCT, RHHBY
Occurred on: May 07, 2019
Phase III KATHERINE data presented of Kadcyla vs Herceptin in HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Ticker: RHHBY
Occurred on: Oct 15, 2018
Genentech’s (RHHBY) Phase 3 Data Presented of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and etoposide)in Previously-Untreated Extensive-Stage Small Cell Lung Cancer
Ticker: RHHBY
Occurred on: Jun 24, 2018
Celgene Expected to Complete Four Phase 3 Trials of ABRAXANE in Different Indications in 2017
Tickers: CELG, RHHBY
Occurred on: Jan 19, 2018
FDA Action Date of September 3rd for Mylan (MYL) and Biocon's Biologics License Application (BLA) For MYL-14010, a Biosimilar to Roche's (RHHBY) Breast Cancer Med Herceptin
Tickers: MYL, RHHBY, Biocon Ltd.
Occurred on: Jul 13, 2017
Roche Begins Enrolling Patients in Inhibitor Phase 3 Study of Emicizumab - Expects to Begin Non-Inhibitor Phase 3 Study and Pediatrics Inhibitor Phase 2 Study in 2016
Ticker: RHHBY
Occurred on: Jun 26, 2017
Having used Halozyme Therapuetics' ENHANZE technology ,Roche’s is awaiting June FDA action date on rituximab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma
Tickers: RHHBY, HALO
Occurred on: Jun 23, 2017
Roche Expands Atezolizumab Cancer Immunology Portfolio - Eleven Phase 1b Readouts expected in 2016
Ticker: RHHBY
Occurred on: Jun 03, 2017
Phase 3 LAVOLTA III Study Readout of Lebrikizumab For Severe Asthma Expected mid 2017
Ticker: RHHBY
Occurred on: May 19, 2017
Clovis (CLVS) Expects to Begin Enrolling Patients in Q1 2017 for Phase 1b Combination Study Evaluating Rucaparib with Genentech's (RHHBY) Tecentriq in Solid Tumors and Gynecologic Cancers
Tickers: CLVS, RHHBY, Genentech
Occurred on: May 03, 2017
Roche's (RHHBY) Tecentriq Approved by FDA for Advanced Bladder Cancer
Ticker: RHHBY
Occurred on: Apr 18, 2017
Alecensa (alectinib) Phase 3 ALEX Study Results Expected mid-2017 - Roche Seeking Approval in Japan
Ticker: RHHBY
Occurred on: Apr 10, 2017
OCREVUS (ocrelizumab) for the treatment of RMS and PPMS, and has extended the application Priority Review Designation with a targeted action date of 28th March 2017
Ticker: RHHBY
Occurred on: Mar 29, 2017
Roche's (RHHBY) Rituxan Designated a Breakthrough Therapy by FDA for Pemphigus Vulgaris, a Rare Autoimmune Skin Disorder
Ticker: RHHBY
Occurred on: Mar 24, 2017
Roche (RHHBY) Phase 3 APHINITY Results Expected in Q1 2017 Evaluating Perjeta in Adjuvant Breast Cancer
Ticker: RHHBY
Occurred on: Mar 02, 2017
Agenus (AGEN) Shuts Down Phase 2 Study Assessing Prophage G-200 + Roche's (RHHBY) Avastin in Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Tickers: AGEN, RHHBY
Occurred on: Feb 22, 2017
European Commission (EC) Approves Roche's (RHHBY) Alecensa for Adult Patients with Anaplastic Lymphoma Kinase ALK-Positive Advanced Non-Small Cell Lung Cancer Who Have Taken Pfizer's (PFE) Xalkori (Crizotinib)
Tickers: RHHBY, PFE
Occurred on: Feb 21, 2017
FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation
Ticker: RHHBY
Occurred on: Jan 06, 2017
Genentech (RHHBY) Presents Phase 3 HAVEN 1 Results Evaluating Emicizumab in Patients at Least 12 Years Old with Hemophilia A and Inhibitors to Factor VIII
Tickers: RHHBY, Genentech
Occurred on: Dec 22, 2016
Roche (RHHBY) Launches DISCOVERY 5-Plex Procedure for Ventana System
Ticker: RHHBY
Occurred on: Nov 21, 2016
Phase III GiACTA study shows Roche’s (RHHBY) Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis
Ticker: RHHBY
Occurred on: Nov 12, 2016
Mylan (MYL) and Biocon Submit Biologics License Application (BLA) to FDA for Biosimilar to Roche's (RHHBY) Herceptin for HER2-Positive Breast and Gastric Cancers
Tickers: MYL, RHHBY, Biocon Ltd.
Occurred on: Nov 08, 2016
Roche (RHHBY) Initiates Two Phase 3 Studies Evaluating Tecentriq + Cotellic + Zelboraf in Patients with Advanced Melanoma
Ticker: RHHBY
Occurred on: Nov 07, 2016
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Rituximab
Tickers: HALO, RHHBY
Occurred on: Nov 03, 2016
FDA Grants Priority Review to Atezolizumab - Biologics License Application Date set for September 12, 2016
Ticker: RHHBY
Occurred on: Oct 19, 2016
Roche's (RHHBY) Lucentis Prefilled Syringe Approved by FDA
Tickers: RHHBY, Genentech
Occurred on: Oct 14, 2016
Roche's (RHHBY) Lucentis sBLA Granted Priority Review by FDA for Treatment of Myopic Choroidal Neovascularization
Ticker: RHHBY
Occurred on: Oct 11, 2016
Roche (RHHBY) Announces Phase 3 OAK Data Evaluating TECENTRIQ Versus Chemotherapy in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ticker: RHHBY
Occurred on: Oct 10, 2016
FDA grants breakthrough therapy designation for Roche’s (RHHBY) Actemra/RoActemra in giant cell arteritis, a form of vasculitis
Ticker: RHHBY
Occurred on: Oct 05, 2016
US FDA grants Breakthrough Therapy Designation for Roche's (RHHBY) Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
Ticker: RHHBY
Occurred on: Oct 04, 2016
Roche (RHHBY) Releases New Analyses from Three Phase III Studies of OCREVUS in Relapsing Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS)
Ticker: RHHBY
Occurred on: Sep 14, 2016
Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy
Ticker: RHHBY
Occurred on: Sep 01, 2016
Anti-Cancer Agent “Xeloda”, Obtained Approval for Additional Indication of “Adjuvant Chemotherapy for Rectal Cancer”
Ticker: RHHBY
Occurred on: Aug 26, 2016
Roche’s emicizumab continued to show promising safety and efficacy profile in long-term study in people with severe haemophilia A
Ticker: RHHBY
Occurred on: Jul 28, 2016
GOYA study did not meet its primary endpoint of improvement in progression-free survival with Gazyva plus CHOP chemotherapy versus Rituxan plus CHOP chemotherapy
Ticker: RHHBY
Occurred on: Jul 17, 2016
Organovo and Roche Researchers Publish Data Demonstrating Superiority of 3D Bioprinted Human Liver Tissues in Assessing Drug-Induced Toxicity
Tickers: ONVO, RHHBY
Occurred on: Jul 11, 2016
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
Ticker: RHHBY
Occurred on: Jul 07, 2016
Roche Plans to File for Marketing Authorization and Submit Data to Global Regulatory Authorities for Ocrelizumab
Ticker: RHHBY
Occurred on: Jun 28, 2016
Roche receives FDA clearance for its Procalcitonin (PCT) assay to help clinicians effectively assess sepsis risk and manage sepsis patients
Ticker: RHHBY
Occurred on: Jun 23, 2016
Roche’s Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
Ticker: RHHBY
Occurred on: Jun 16, 2016
Genentech’s Cancer Immunotherapy Tecentriq (atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
Ticker: RHHBY
Occurred on: Jun 05, 2016
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
Tickers: EXEL, RHHBY
Occurred on: Jun 05, 2016
Phase III Study Shows Genentech’s Actemra (tocilizumab) Maintained Steroid-Free Remission in People with Giant Cell Arteritis (GCA)
Ticker: RHHBY
Occurred on: Jun 05, 2016
Anti-Cancer Agent “Avastin” Obtained Approval for Additional Indication of Advanced or Recurrent Cervical Cancer
Ticker: RHHBY
Occurred on: May 23, 2016
AbbVie Receives FDA Accelerated Approval of Venclexta (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion
Tickers: ABBV, RHHBY
Occurred on: Apr 11, 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Ticker: RHHBY
Occurred on: Apr 11, 2016
Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol
Ticker: RHHBY
Occurred on: Mar 31, 2016
Roche receives China Food and Drug Administration (CFDA) approval for the CINtec PLUS Cytology test to help prevent women from developing cervical cancer
Ticker: RHHBY
Occurred on: Mar 08, 2016
Roche Releases Data on 2 Identical Phase 3 Studies of Lebrikizumab for the Treatment of Severe Asthma
Ticker: RHHBY
Occurred on: Feb 29, 2016
FDA approves Roche’s Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma
Ticker: RHHBY
Occurred on: Feb 29, 2016
Roche's Ocrelizumab Granted Breakthrough Therapy Designation by FDA
Ticker: RHHBY
Occurred on: Feb 17, 2016
JHL Biotech Receives Approval From European Authorities to Begin JHL1101 Rituximab Biosimilar Clinical Trial and is the First Biotech Company in Greater China Region to Receive European Approval
Tickers: 6540.TWO, RHHBY
Occurred on: Feb 15, 2016
Chugai's ALK Inhibitor Alecensa Trial Stopped Early for Benefit Demonstrates Statistically Significant Improvement in PFS in a Japanese Phase III Head to Head Study with Crizotinib
Ticker: RHHBY
Occurred on: Feb 10, 2016
With Cotellic + Zelboraf Combination Approved, Roche Looks to Develop Triple Combination Treatments With Atezolizumab
Ticker: RHHBY
Occurred on: Jan 28, 2016
Largest Breast Cancer Study of its Kind Suggests Several New Potential Drug Targets and Combinations; results will be seized on by labs worldwide to identify new drug candidates and pinpoint mechanisms by which cancer cells resist treatment
Tickers: NVS, RHHBY
Occurred on: Jan 14, 2016
FDA grants Priority Review for venetoclax NDA
Ticker: RHHBY
Occurred on: Jan 12, 2016
Tensha Therapeutics To Be Acquired By Roche
Ticker: RHHBY
Occurred on: Jan 11, 2016
Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Ticker: RHHBY
Occurred on: Jan 08, 2016

Strategic Initiatives (RHHBY)

Inflazome announces acquisition by Roche (RHHBY)
Ticker: RHHBY
Announcement Date: Sep 21, 2020
Roche (RHHBY) buys cancer-focused oncology-specific electronic health record software developer Flatiron Health
Ticker: RHHBY
Announcement Date: Feb 15, 2018
Roche (RHHBY) Agrees to Acquire Eye Drug Maker ForSight VISION4
Ticker: RHHBY
Announcement Date: Jan 10, 2017
Roche (RHHBY) and Bristol-Myers Squibb (BMY) Announce Decrease in Cancer Drug Prices for Access to Britain's National Health Service (NHS)
Tickers: BMY, RHHBY
Announcement Date: Nov 17, 2016
Roche (RHHBY) and Halozyme (HALO) Sign Collaboration Agreement to Evaluate PEGPH20 and Tecentriq in Eight Types of Tumors
Tickers: HALO, RHHBY
Announcement Date: Nov 10, 2016
Novogen (NVGN) Licenses GDC-0084 for Gioblastoma from Genentech (RHBBY)
Tickers: RHHBY, NVGN, Genentech
Announcement Date: Oct 31, 2016
Eleven Biotherapeutics Announces Signing of Exclusive License Agreement
Tickers: EBIO, RHHBY, SESN
Announcement Date: Jun 13, 2016
Lilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool
Tickers: LLY, RHHBY
Announcement Date: Jan 27, 2016
Catalent Biologics Announces Research Collaboration With Roche On SMARTag Technology
Tickers: CTLT, RHHBY
Announcement Date: Jan 13, 2016